Calliditas: The European CHMP opinion is a timely value trigger

Research Note



The positive CHMP opinion is both timely and expected. The next step is a Q3 European approval allowing Calliditas partner Stada to launch Kinpeygo in Europe. We can also look forward to the Part B readout in early 2023, which is likely to support both sales and the process of converting the conditional approval to unconditional approval.


Johan Unnerus

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.